Gate Bioscience is a Brisbane, California biotech building a brand-new class of medicines it calls Molecular Gates: oral small molecules that stop disease-causing proteins from ever leaving the cell. Instead of chasing proteins after they are secreted into the body, Gate's drugs bind Sec61, the single channel every one of the roughly 4,000 human secreted and membrane proteins must pass through, and selectively block a target protein so the cell degrades it. Founded in 2021 and emerged from stealth in 2023 with $60M, the company has raised about $135M total and is pushing its lead programs toward IND-enabling studies and Phase 1 trials.
Jordi Mata-Fink is the co-founder and CEO of Gate Bioscience, a Brisbane, California biotech building an entirely new class of small-molecule drugs called Molecular Gates. The idea is deceptively simple and technically audacious: instead of chasing disease-causing proteins after they leave the cell, Gate's molecules park inside the cell's secretory channel (Sec61) and selectively stop a single harmful protein from ever getting out, while letting everything else pass. A chemical engineer trained at Stanford and MIT, Mata-Fink spent years inside Flagship Pioneering helping spin up companies like Editas and Rubius before founding Gate in 2021. The company emerged from stealth in 2023 with $60M, and in November 2025 raised an oversubscribed $65M Series B led by Forbion with Eli Lilly joining, pushing total funding to $135M as it heads toward the clinic. He coaches youth soccer on the side.